domingo, 11 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Citigroup Q4 Earnings on the Deck: How to Approach the Stock Now?

View original at finance.yahoo.com
Citigroup Q4 Earnings on the Deck: How to Approach the Stock Now? Citigroup Inc. C is slated to report fourth-quarter and full-year 2025 results on Jan…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Branded Cards net credit loss (NCL) is expected to be 3.50-4%

    80% confidence
  • Management expects IB fees to increase in the mid-20s (percentage) year over year in the fourth quarter

    80% confidence
  • Citigroup expects revenues to cross $84 billion compared with the prior mentioned $84.1 billion

    80% confidence
  • Retail Services NCL is expected to be 5.75-6.25%

    80% confidence
  • The transaction is expected to result in a pre-tax loss of $1.2 billion in the fourth quarter of 2025

    80% confidence
  • The Zacks Consensus Estimate for fourth-quarter sales is pegged at $20.94 billion, indicating a 6.9% year-over-year increase

    80% confidence
  • Management anticipates expenses to be higher than $53.4 billion, including the impacts of FX translation and excluding the goodwill impairment

    80% confidence
  • The company is seeing continued momentum, particularly in M&A

    80% confidence
  • Management expects NII (excluding Markets) to rise 5.5% on a year-over-year basis

    80% confidence
  • Citigroup expects market revenues to be down in the low to mid-single digit in the fourth quarter from a year ago

    80% confidence
  • The efficiency ratio is expected to be slightly less than 64%

    80% confidence
  • The consensus estimate for earnings for the to-be-reported quarter has been revised downward to $1.65 over the past seven days, indicating a 23.1% rise from the prior-year quarter's actual

    80% confidence
  • Its earnings outpaced the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 13.19%

    80% confidence

Data points we hold from this source

Citigroup Inc. · forward pe ratio11.92 ratio
Citigroup Inc. · non accrual loans3.7 billion_USD
Citigroup Inc. · principal transactions income2.1 billion_USD
Citigroup Inc. · efficiency ratio64 percent
Citigroup Inc. · revenue20.94 billion_USD
Citigroup Inc. · revenue84 billion_USD
Citigroup Inc. · average interest earning assets2.5 trillion_USD
Citigroup Inc. · commissions and fees2.9 billion_USD
Citigroup Inc. · market revenue4.5 billion_USD
Citigroup Inc. · net interest income14.9 billion_USD
Citigroup Inc. · non interest income5.9 billion_USD
Citigroup Inc. · administration and fiduciary fees1.0 billion_USD
Citigroup Inc. · stock repurchase authorization remaining11.3 billion_USD
Citigroup Inc. · dividend per share0.60 USD
Board of Governors of the Federal Reserve System · fed funds rate3.50-3.75 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,369 documentos-fonte arquivados
Consulte estes dados → isubstrate.com